Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Aug 6, 2009

Eden Biodesign to Manufacture Wound Healing Compound for Omnio

  • Swedish company Omnio Healer selected Eden Biodesign to carry out process development and cGMP mammalian cell manufacture of its lead recombinant protein candidate, which is in development for the treatment of chronic eardrum wounds. The candidate is currently in late preclinical development and is expected to enter the clinic during late 2010.

    One of Karolinska Development’s portfolio companies, Omnio Healer was established in 2006 to exploit the proinflammatory properties of the anticoagulation system for applications in wound healing and anti-infectives.



Related content

Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »